⌘K
t
| Date | 27 Sept 2023 |
| Time | 16:16:08 |
| Category | Miscellaneous |
| ID | 8843N |
EDX Medical Group PLC
Annual General Meeting
Result of Annual General Meeting
The Annual General Meeting of EDX Medical Group Plc was held at Roosevelt Room, Brown's Hotel, 33 Albemarle St, London, W1S 4BP on 27 September 2023 at 2:00 p.m.
All seven resolutions put to members were passed on a poll. Resolutions 1 to 5 were passed as ordinary resolutions and resolutions 6 and 7 were passed as special resolutions.
The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:
|
Resolution |
Votes for |
% |
Votes against |
% |
Votes withheld |
|
Resolution 1 (Ordinary) To elect Jason Holt as a director of the Company |
148,033,333 |
100.00 |
0 |
0.00 |
0 |
|
Resolution 2 (Ordinary) To elect Dr Michael Hudson as a director of the Company |
148,033,333 |
100.00 |
0 |
0.00 |
0 |
|
Resolution 3 (Ordinary) To elect Professor Sir Christopher Evans OBE as a director of the Company |
148,033,333 |
100.00 |
0 |
0.00 |
0 |
|
Resolution 4 (Ordinary) To elect Professor Trevor Jones CBE as a director of the Company |
148,033,333 |
100.00 |
0 |
0.00 |
0 |
|
Resolution 5 (Ordinary) To authorise the Directors to allot shares in the Company |
148,033,333 |
100.00 |
0 |
0.00 |
0 |
|
Resolution 6 (Special) To disapply statutory pre-emption rights generally |
148,033,333 |
100.00 |
0 |
0.00 |
0 |
|
Resolution 7 (Special) To disapply statutory pre-emption rights pursuant to an acquisition or other capital investment |
148,033,333 |
100.00 |
0 |
0.00 |
0 |
As at 27 September 2023, there were 291,875,000 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.
The full text of each resolution is available in the Notice of Annual General Meeting, published on our website.
Contacts:
|
EDX Medical PLC |
|
|
Dr Mike Hudson (Chief Executive Officer) |
+44 (0)7812 345 301 mike@edxmedical.co.uk |
|
|
|
|
Oberon Capital |
|
|
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking) |
+44 (0)20 3179 5300 |
|
|
|
|
Media House International |
|
|
Ramsay Smith (Executive Director)
Gary McQueen (Associate Director) |
+44 (0)7788 414856 ramsay@mediahouse.co.uk +44 (0)7834 694609 gary@mediahouse.co.uk |
Notes for Editors:
About EDX Medical Group
EDX Medical Group PLC develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease, neurology and infectious diseases. The company is listed on the Access Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.
EDX Medical operates a molecular biology and diagnostics laboratory in Cambridge, UK, and the 100%-owned subsidiary "Torax Biosciences Ltd" (www.toraxbiosciences.co.uk) with a satellite operation in Ireland. EDX Medical provides testing and genomic sequencing services, undertakes quality assurance, conducts research & development (R&D) and has established expertise in the design, development, validation and sourcing of diagnostic testing solutions to ISO 13485. Key laboratory tests performed by the Company have been accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).